How to Find Hidden Profit in Your Claims Data

What NDC optimization actually is

NDC optimization is the discipline of finding the most profitable way to legally and clinically fill every prescription that walks through your door. It is not fraud. It is not switching patients to inferior products. It is using the flexibility that already exists in the prescribing and dispensing process to capture margin that most pharmacies are giving up by default.

Every drug in America has multiple NDC numbers. Same active ingredient, same strength, same dosage form, but different manufacturers, different package sizes, different labeler codes. Each one of those NDCs has a different cost to you and a different reimbursement from each PBM. The reimbursement you get is tied to the exact NDC you dispense. That is the opening.

Most pharmacies dispense whatever their wholesaler sends them. The wholesaler picks based on their own margin and inventory, not yours. The pharmacy accepts what shows up, fills the prescription, and moves on. Meanwhile there is a different NDC of the exact same drug sitting in the same distribution channel that would have paid $40 more per fill.

Multiply that across a few thousand prescriptions a month and you have the six figure opportunity I talk about constantly.

The core concepts you have to understand first

The four categories of NDC optimization plays

Every optimization opportunity falls into one of four categories. Understanding the categories is how you know where to look and what to do when you find it.

1. Manufacturer switches (same drug, different labeler)

The simplest play and usually the biggest one. A generic drug has multiple manufacturers. Your wholesaler has several in stock. Each one has a different cost and potentially a different reimbursement. You dispense Manufacturer A today and the PBM pays $80. You dispense Manufacturer B tomorrow for the same patient and the same drug and the PBM pays $120.

The underlying drug is pharmaceutically equivalent. The patient sees no difference. The prescriber does not need to be called. The only difference is the manufacturer on the label, and that difference is worth $40 to your pharmacy.

Most pharmacies have no idea this is happening because nobody is checking. Your auto-dispense is grabbing whatever the wholesaler sent, and whatever the wholesaler sent may be the worst possible option from your margin standpoint.

2. Package size optimization

A 90 count bottle of a drug and a 500 count bottle of the same drug are not just different sizes. They are often different NDCs with different reimbursement profiles. Sometimes the PBM pays a per unit rate that is much higher on one package size versus another. Sometimes the acquisition cost is different in a way that changes the margin calculation entirely.

The move is to identify which package size produces the best margin for each drug you dispense frequently and standardize your ordering around that size. It requires a small change in your wholesaler ordering but the impact compounds fast.

3. Therapeutic interchange

This is the big play and also the one that requires the most care. A therapeutic interchange is switching from one drug to a different drug in the same class that is clinically equivalent but more profitable. A common example is switching within a class of statins, PPIs, or SSRIs where the clinical differences are minimal but the margin differences are huge.

Therapeutic interchanges require prescriber approval. You cannot do them without a new prescription. The workflow is: identify the opportunity, call or fax the prescriber's office with the clinical rationale and the proposed switch, get a new prescription for the new drug, fill the new prescription, document the interchange.

Done right this process takes about five minutes of technician time per interchange and produces $50 to $300 in additional gross profit. That is a ratio nobody in any other industry would walk past.

4. Brand vs generic where generic pays better

Counterintuitive but real. Sometimes a brand name drug has a dramatically higher reimbursement than its generic equivalent because of how specific PBM contracts are structured. You assume the generic is always more profitable because you pay less for it. But if the reimbursement gap is bigger than the cost gap, the brand is actually the profit play.

This one requires constant attention because brand-generic relationships flip based on PBM contract changes. A brand that was unprofitable last month might be profitable this month if the PBM updated their MAC. The only way to catch these is with systematic data mining.

How do I actually find these opportunities in my data?

The manual process works but it is brutally slow. You pull your dispensing history, filter for drugs you fill frequently, look up each one against your PBM MACs, check your wholesaler catalog for alternative NDCs, calculate the margin on each option, and identify the switches. Then you repeat the whole thing next week because the MACs just updated.

For most pharmacies, this manual approach produces maybe 10 to 20 percent of the actual opportunities hiding in their data. The other 80 percent slip through because the math is too complex and the data is too high volume for a human to process weekly.

The honest answer is that this is a software problem. Human beings are not going to beat a system that scans 3,000 claims a night and flags every opportunity automatically. But the manual version is worth doing anyway because it teaches you what the opportunities look like, and that intuition pays off when you do eventually move to an automated solution.

The starter manual process

1. Pull your top 50 drugs by dispense volume. Those 50 drugs are where 70 to 80 percent of your margin lives. Optimizing those first gets you most of the win without boiling the ocean.
2. For each drug, list every NDC you could possibly dispense. Your wholesaler catalog will show all options. Ignore anything you cannot actually order.
3. Look up the current reimbursement for each NDC across your top PBMs. This is the painful part because reimbursement data is not centralized anywhere friendly. You can pull historical data from your PMS reports on prior fills.
4. Subtract acquisition cost from reimbursement. Now you have margin per NDC per PBM. The pattern will become immediately obvious. For any given drug, there is almost always one NDC that is clearly better than the others.
5. Update your dispensing defaults. For each drug, set the preferred NDC as your standard dispense choice. Train your team to dispense that NDC unless there is a specific reason not to.
6. Rebuild the list quarterly. MACs change. Manufacturer pricing changes. PBM contracts change. Whatever was optimal last quarter may not be optimal now. Plan on redoing this every three months at minimum.

The therapeutic interchange workflow

Therapeutic interchanges deserve their own section because they are the highest leverage play and also the one that requires the most disciplined workflow. Get sloppy here and you will either annoy prescribers or expose yourself to clinical liability. Done right they are the single biggest profit lever in the program.

Step 1: Identify the opportunity

The ideal candidate for a therapeutic interchange is a patient on a high volume, high cost drug in a class where there are clinically equivalent alternatives with better economics. Statins. PPIs. SSRIs. Antihypertensives. ARBs. Most chronic maintenance medications have at least one interchange opportunity.

Step 2: Verify clinical appropriateness

Before you make the call, the pharmacist has to verify that the switch is clinically appropriate for the specific patient. Not just that the drugs are in the same class. That the specific patient has no contraindications to the proposed drug. That the dosing can be matched. That there are no known reactions or prior failures on the proposed drug.

This is a pharmacist decision, not a technician decision. The technician can flag the opportunity, but the pharmacist has to approve it before anyone contacts the prescriber.

Step 3: Communicate with the prescriber

Contact the prescriber's office with a specific, clinical, professional request. Do not make it about the money. Make it about the patient and the clinical equivalence. Here is the format I use:

Most prescribers approve these requests without argument because they trust the pharmacist's clinical judgment and they have no stake in which specific drug the patient gets as long as the outcome is the same. The ones who push back usually have a specific reason, which is fine. Document it and move on to the next opportunity.

Step 4: Fill the new prescription and document

Once you have the new prescription, fill it normally. Document the interchange in the patient record so the team knows why the switch happened and so you can track the cumulative impact of your program over time.

The mistakes that kill NDC optimization programs

I have watched pharmacies try to implement NDC optimization and fail for the same reasons every time. Here is what goes wrong.

• Treating it as a project instead of a process. A pharmacy will spend two weeks optimizing their top 50 drugs, see a nice bump in profit, then stop. Three months later the MACs have changed and they are back where they started. This is not a project. It is an ongoing discipline.
• Optimizing without clinical review. Having technicians make interchange decisions without pharmacist oversight. Doing this once will cost you a patient and potentially a license.
• Ignoring the package size dimension. Most pharmacies optimize manufacturer but never think about package size. The package size play is often bigger than the manufacturer play.
• Not tracking the impact. Owners run the program for a month, feel good about it, and move on without ever measuring the actual dollar impact. You cannot improve what you do not measure. Put a number on it every month.
• Waiting for software to solve the problem. You do not need software to start. You need a list of 50 drugs and a spreadsheet. The software makes it faster and more complete later, but the manual version works and you should not let "we are looking at software" be an excuse to do nothing for six months.
• Forgetting the patient is the point. Every dispensing decision has to work for the patient first. An optimization that saves the patient money or keeps their regimen the same is easy. An optimization that costs the patient something is not optimization, it is just shifting the cost.

What success actually looks like

A mature NDC optimization program at an independent pharmacy looks like this. Every week, the pharmacy reviews its top volume drugs against current MAC data and updates dispensing defaults. Technicians know which NDC to pick for each of the common drugs. The pharmacist is reviewing therapeutic interchange opportunities weekly and calling prescriber offices to get two or three approved per day. The dispensing software is flagging opportunities in real time as prescriptions come in. The monthly P&L shows a steadily growing "optimization capture" line that did not exist a year ago.

For a typical independent pharmacy doing 2,500 to 4,000 scripts per month, a well-run NDC optimization program produces $5,000 to $15,000 in additional monthly gross profit. Some pharmacies I have worked with are well above that range. The bottleneck is not the opportunity. The opportunity is always there. The bottleneck is whether the pharmacy has the discipline and the tools to capture it systematically.

Start with the top 50 drugs. Build the spreadsheet. Make the first round of switches this week. Measure the impact next month. Then do it again. That is how you start.